JP4990164B2 - セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体 - Google Patents

セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体 Download PDF

Info

Publication number
JP4990164B2
JP4990164B2 JP2007554065A JP2007554065A JP4990164B2 JP 4990164 B2 JP4990164 B2 JP 4990164B2 JP 2007554065 A JP2007554065 A JP 2007554065A JP 2007554065 A JP2007554065 A JP 2007554065A JP 4990164 B2 JP4990164 B2 JP 4990164B2
Authority
JP
Japan
Prior art keywords
methyl
pyrrole
hexahydroindeno
mmol
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007554065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508365A (ja
JP2008508365A5 (enExample
Inventor
ベンナニ，ユセフ・エル
ハツク，バヤード
ロバージ，マイケル・ジエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athersys Inc
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of JP2008508365A publication Critical patent/JP2008508365A/ja
Publication of JP2008508365A5 publication Critical patent/JP2008508365A5/ja
Application granted granted Critical
Publication of JP4990164B2 publication Critical patent/JP4990164B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007554065A 2004-07-29 2005-07-26 セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体 Expired - Fee Related JP4990164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59204704P 2004-07-29 2004-07-29
US60/592,047 2004-07-29
PCT/US2005/026415 WO2007081299A2 (en) 2004-07-29 2005-07-26 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators

Publications (3)

Publication Number Publication Date
JP2008508365A JP2008508365A (ja) 2008-03-21
JP2008508365A5 JP2008508365A5 (enExample) 2008-06-05
JP4990164B2 true JP4990164B2 (ja) 2012-08-01

Family

ID=37075566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007554065A Expired - Fee Related JP4990164B2 (ja) 2004-07-29 2005-07-26 セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体

Country Status (16)

Country Link
US (5) US20060025601A1 (enExample)
EP (1) EP1841738A4 (enExample)
JP (1) JP4990164B2 (enExample)
KR (2) KR20130047765A (enExample)
CN (1) CN101516372A (enExample)
AR (1) AR050274A1 (enExample)
AU (1) AU2005333518B2 (enExample)
BR (1) BRPI0512869A (enExample)
CA (1) CA2603249C (enExample)
IL (1) IL180977A (enExample)
NO (1) NO20071102L (enExample)
NZ (1) NZ552806A (enExample)
RU (1) RU2007107494A (enExample)
TW (1) TWI377195B (enExample)
WO (1) WO2007081299A2 (enExample)
ZA (1) ZA200700684B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025601A1 (en) 2004-07-29 2006-02-02 Athersys, Inc. Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP4866901B2 (ja) 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3081213B1 (en) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Tricyclic compound
TW201041851A (en) 2009-03-10 2010-12-01 Organon Nv Tricyclic heterocyclic derivatives
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN106380440B (zh) * 2016-08-30 2019-02-01 华东师范大学 一种茚酮并吡咯类衍生物及其合成方法和应用
CN106631989B (zh) * 2016-11-26 2019-07-16 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3576334D1 (de) * 1984-07-25 1990-04-12 Abbott Lab 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde.
US4622405A (en) * 1984-07-25 1986-11-11 Abbott Laboratories 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension
EP0422134B1 (en) * 1988-12-15 1996-06-12 Abbott Laboratories 5-ht selective agents
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
US5244888A (en) * 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US7351711B2 (en) * 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20060025601A1 (en) * 2004-07-29 2006-02-02 Athersys, Inc. Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators

Also Published As

Publication number Publication date
AU2005333518B2 (en) 2010-12-02
NO20071102L (no) 2007-04-20
KR20080025657A (ko) 2008-03-21
US20090239925A1 (en) 2009-09-24
AR050274A1 (es) 2006-10-11
TW200619196A (en) 2006-06-16
CN101516372A (zh) 2009-08-26
AU2005333518A1 (en) 2007-02-22
US8716324B2 (en) 2014-05-06
EP1841738A4 (en) 2010-06-02
KR101257233B1 (ko) 2013-04-29
TWI377195B (en) 2012-11-21
US7935830B2 (en) 2011-05-03
US20110172283A1 (en) 2011-07-14
KR20130047765A (ko) 2013-05-08
BRPI0512869A (pt) 2008-04-08
ZA200700684B (en) 2008-10-29
WO2007081299A3 (en) 2007-09-20
NZ552806A (en) 2009-09-25
US20060025601A1 (en) 2006-02-02
IL180977A (en) 2012-08-30
US20140206739A1 (en) 2014-07-24
RU2007107494A (ru) 2008-09-10
CA2603249A1 (en) 2007-07-19
JP2008508365A (ja) 2008-03-21
US20120252859A1 (en) 2012-10-04
US8232311B2 (en) 2012-07-31
CA2603249C (en) 2014-01-21
US9096520B2 (en) 2015-08-04
EP1841738A2 (en) 2007-10-10
WO2007081299A2 (en) 2007-07-19
AU2005333518A8 (en) 2008-08-07
IL180977A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
US7935830B2 (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
JP5188986B2 (ja) セロトニン５−ｈｔ２ｃ受容体のリガンドとしてのチオフェニルおよびピロリルアゼピンならびにこの使用
US7981919B2 (en) Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
US20100190772A1 (en) Substituted Azepine Derivatives As Serotonin Receptor Modulators
MXPA02000978A (es) Antagonistas del receptor de quimioquina y metodosde uso de los mismos.
US5665722A (en) Benzofuran derivatives as D4 receptor antagonists
US9309262B2 (en) Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US5681836A (en) Methanesulfonate salts of antipsychotic benzofuran derivatives
MX2007001061A (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
MXPA06013392A (en) Substituted azepine derivatives as serotonin receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120424

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120501

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees